Kaken Finds Efinaconazole Licensing Partner In Canada’s Variant
This article was originally published in PharmAsia News
Executive Summary
Kaken Pharmaceuticals has agreed to provide Canadian firm Variant with preparation technology for the world`s first external triazole, efinaconazole, used in the treatment of onychomycosis.